KR20210041589A - 생체이용 가능한 경구 투여형 - Google Patents

생체이용 가능한 경구 투여형 Download PDF

Info

Publication number
KR20210041589A
KR20210041589A KR1020217006355A KR20217006355A KR20210041589A KR 20210041589 A KR20210041589 A KR 20210041589A KR 1020217006355 A KR1020217006355 A KR 1020217006355A KR 20217006355 A KR20217006355 A KR 20217006355A KR 20210041589 A KR20210041589 A KR 20210041589A
Authority
KR
South Korea
Prior art keywords
compound
sdi
subject
formulation
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217006355A
Other languages
English (en)
Korean (ko)
Inventor
맨더 브이. 달리
에이케이엠 나지르 우딘
Original Assignee
피티씨 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67766269&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20210041589(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 피티씨 테라퓨틱스, 인크. filed Critical 피티씨 테라퓨틱스, 인크.
Publication of KR20210041589A publication Critical patent/KR20210041589A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020217006355A 2018-08-03 2019-08-02 생체이용 가능한 경구 투여형 Ceased KR20210041589A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862714182P 2018-08-03 2018-08-03
US62/714,182 2018-08-03
PCT/US2019/044853 WO2020028778A1 (en) 2018-08-03 2019-08-02 Bioavailable oral dosage forms

Publications (1)

Publication Number Publication Date
KR20210041589A true KR20210041589A (ko) 2021-04-15

Family

ID=67766269

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217006355A Ceased KR20210041589A (ko) 2018-08-03 2019-08-02 생체이용 가능한 경구 투여형

Country Status (23)

Country Link
US (1) US20210205225A1 (https=)
EP (1) EP3829544A1 (https=)
JP (1) JP2021532193A (https=)
KR (1) KR20210041589A (https=)
CN (1) CN112752570A (https=)
AR (1) AR115913A1 (https=)
AU (1) AU2019316036A1 (https=)
BR (1) BR112021001859A2 (https=)
CA (1) CA3107737A1 (https=)
CL (1) CL2021000271A1 (https=)
CO (1) CO2021001979A2 (https=)
CR (1) CR20210093A (https=)
EA (1) EA202190429A1 (https=)
EC (1) ECSP21011795A (https=)
IL (1) IL280471A (https=)
MX (1) MX2021001364A (https=)
NI (1) NI202100006A (https=)
PE (1) PE20211410A1 (https=)
PH (1) PH12021550237A1 (https=)
SG (1) SG11202100984VA (https=)
TN (1) TN2021000021A1 (https=)
TW (1) TW202019414A (https=)
WO (1) WO2020028778A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX373926B (es) 2009-05-27 2020-07-10 Ptc Therapeutics Inc Metodos para tratar cancer y estados no neoplasicos.
EP3664803A4 (en) 2017-08-01 2021-05-05 PTC Therapeutics, Inc. DHODH INHIBITOR FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCERS
CN112028888B (zh) * 2020-09-11 2021-08-20 中国药科大学 一种化合物及其制备方法和用途
US20250186437A1 (en) 2021-12-31 2025-06-12 Ptc Therapeutics, Inc. Carboline compounds and use thereof
US20220151938A1 (en) * 2022-01-28 2022-05-19 Ptc Therapeutics, Inc. Tablet for use in treating huntington's disease and method of making the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050249799A1 (en) 2004-03-03 2005-11-10 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
UA92317C2 (ru) 2004-03-15 2010-10-25 Пи-Ти-Си ТЕРАПЬЮТИКС, ИНК. Производные карболина, пригодные для ингибирования развития кровеносных сосудов
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US20100158858A1 (en) 2007-04-13 2010-06-24 Liangxian Cao Administration of carboline derivatives useful in the treatment of cancer and other diseases
DK2200588T3 (da) 2007-09-25 2019-07-01 Solubest Ltd Sammensætninger, som omfatter lipofile aktive forbindelser, og fremgangsmåde til fremstilling deraf
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
MX373926B (es) * 2009-05-27 2020-07-10 Ptc Therapeutics Inc Metodos para tratar cancer y estados no neoplasicos.
US20120202801A1 (en) * 2009-05-27 2012-08-09 Liangxian Cao Methods for treating breast cancer
WO2017091373A1 (en) * 2015-11-25 2017-06-01 Patheon Development Services Inc. Amorphous dispersion granules and oral dosage forms

Also Published As

Publication number Publication date
EP3829544A1 (en) 2021-06-09
PH12021550237A1 (en) 2021-10-11
CN112752570A (zh) 2021-05-04
ECSP21011795A (es) 2021-03-31
IL280471A (en) 2021-03-25
WO2020028778A1 (en) 2020-02-06
TN2021000021A1 (en) 2022-10-03
TW202019414A (zh) 2020-06-01
AR115913A1 (es) 2021-03-10
MX2021001364A (es) 2021-04-13
CL2021000271A1 (es) 2021-08-20
EA202190429A1 (ru) 2021-06-15
CA3107737A1 (en) 2020-02-06
NI202100006A (es) 2021-05-21
JP2021532193A (ja) 2021-11-25
CO2021001979A2 (es) 2021-03-08
US20210205225A1 (en) 2021-07-08
BR112021001859A2 (pt) 2021-04-27
CR20210093A (es) 2021-05-28
AU2019316036A1 (en) 2021-03-04
SG11202100984VA (en) 2021-02-25
PE20211410A1 (es) 2021-08-02

Similar Documents

Publication Publication Date Title
US20240293406A1 (en) Compositions and methods for treating myelofibrosis
KR20210041589A (ko) 생체이용 가능한 경구 투여형
JP6330118B2 (ja) ベンダムスチンと組み合わせたヒストンデアセチラーゼ阻害剤の製剤とその使用
US20240091201A1 (en) Formulations of deferasirox and methods of making the same
US10034854B2 (en) Pharmaceutical composition with improved bioavailability
CN102056589B (zh) 包含bibw 2992的固体药物制剂
CN119970649A (zh) 非晶型激酶抑制剂制剂及其使用方法
TW201102067A (en) Solid dispersions containing an apoptosis-promoting agent
TW200418457A (en) Oral solid form pharmaceutical and pharmaceutical for the treatment of dysuria
CN110809471A (zh) 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型
HK1204998A1 (en) Combinations of histone deacetylase inhibitor and pazopanib and uses thereof
US20120141586A1 (en) Thrombin receptor antagonist and clopidogrel fixed dose tablet
CA3029948A1 (en) Antidiabetic solid pharmaceutical compositions
EA042654B1 (ru) Биодоступные пероральные дозированные формы
JPWO2015199115A1 (ja) 経口投与用医薬組成物
WO2025250391A1 (en) Compositions and methods for solid forms of ulixertinib
AU2024317636A1 (en) Pharmaceutical composition containing substituted indol-5-ol derivative and use thereof
OA17692A (en) Compositions and methods for treating myelofibrosis.

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210302

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220721

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20241217

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250218

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D